Putting the award page together from the records…
Putting the award page together from the records…
Basilea Pharmaceutica International LTD, Allschwil received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $122.50M obligated so far for health r&d services; health care - other; applied research. It runs to 2032-03-31, or to 2035-12-31 if every option is exercised.
Key facts · data as of Oct 22, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75A50124C00033, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75A50124C00033_7505_-NONE-_-NONE-
Basilea Pharmaceutica International LTD, Allschwil: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
6 actions since 2024-09-18. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-07-28 | P00005 | Option exercised | $30.00M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 3 CLIN0004 AND UPDATE ATTACHMENT 1: STATEMENT OF WORK DATED JUNE 10, 2026. |
| 2026-04-24 | P00004 | Administrative change | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 THROUGH SEPTEMBER 30, 2031, UPDATES ARTICLE V: AGREEMENT ADMINISTRATION, AND ARTICLE VII: OBLIGATION AND PAYMENT, SECTION B. |
| 2025-09-15 | P00003 | Supplemental agreement (work within scope) | $24.71M | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA - EXECUTE CLIN 0003 |
| 2025-07-07 | P00002 | Option exercised | $39.11M | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA |
| 2024-10-10 | P00001 | Administrative change | $0 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA |
| 2024-09-18 | 0 | $28.68M | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗